Education
About Us
Working with TipRanks
Follow Us
Boston Scientific (BSX)
NYSE:BSX
BSX Analyst Ratings
Strong Buy
21 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
BSX Stock 12 Month Forecast
Average Price Target
$126.00
▲(27.30% Upside)
| Highest Price Target$140.00 | Average Price Target$126.00 | Lowest Price Target$115.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
J.P. Morgan
―
Buy
―
Reiterated
09/15/25
TR | OpenAI - 4o
$124→$117
Buy
18.21%
Upside
Reiterated
09/12/25
AI Generated ArticleAI Generated Article
Needham
$121
Buy
22.25%
Upside
Reiterated
09/11/25
Leerink Partners
$126→$127
Buy
28.31%
Upside
Reiterated
09/10/25
BTIG
$127
Buy
28.31%
Upside
Reiterated
09/09/25
Strategic Acquisition of Elutia's Bioenvelope Products Boosts Boston Scientific's Market PositionWe see this as a strong fit for BSX, since the bioenvelope technology can be used for many of the implantable devices in its portfolio. Moreover, it gives the company the ability to offer a product that competes against long-standing incumbent Medtronic's (MDT, Neutral; Analyst: Zimmerman) TYRX pouch. We believe the EluPro bioenvelope may offer clinical and handling advantages over TYRX and expect this to be a relatively low-effort product sale for BSX reps. While there could potentially be other interested acquirers (any ICD/pacemaker manufacturer), we do not expect additional bidders, since BSX and Elutia already have a close partnership. The transaction is expected to close in Q4. Our estimates remain unchanged.
Raymond James
$124
Buy
25.28%
Upside
Reiterated
09/08/25
Oppenheimer
$118→$125
Buy
26.29%
Upside
Upgraded
09/08/25
Bernstein
$130
Buy
31.34%
Upside
Reiterated
09/08/25
Jefferies
$130
Buy
31.34%
Upside
Reiterated
08/11/25
Bank of America Securities
$120
Buy
21.24%
Upside
Reiterated
08/06/25
TD Cowen
$115
Buy
16.19%
Upside
Reiterated
08/06/25
Truist Financial
$120→$125
Buy
26.29%
Upside
Reiterated
07/24/25
Robert W. Baird
$117→$123
Buy
24.27%
Upside
Reiterated
07/24/25
Mizuho Securities
$130→$140
Buy
41.44%
Upside
Reiterated
07/24/25
Canaccord Genuity
$117→$131
Buy
32.35%
Upside
Reiterated
07/24/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
J.P. Morgan
―
Buy
―
Reiterated
09/15/25
TR | OpenAI - 4o
$124→$117
Buy
18.21%
Upside
Reiterated
09/12/25
AI Generated ArticleAI Generated Article
Needham
$121
Buy
22.25%
Upside
Reiterated
09/11/25
Leerink Partners
$126→$127
Buy
28.31%
Upside
Reiterated
09/10/25
BTIG
$127
Buy
28.31%
Upside
Reiterated
09/09/25
Strategic Acquisition of Elutia's Bioenvelope Products Boosts Boston Scientific's Market PositionWe see this as a strong fit for BSX, since the bioenvelope technology can be used for many of the implantable devices in its portfolio. Moreover, it gives the company the ability to offer a product that competes against long-standing incumbent Medtronic's (MDT, Neutral; Analyst: Zimmerman) TYRX pouch. We believe the EluPro bioenvelope may offer clinical and handling advantages over TYRX and expect this to be a relatively low-effort product sale for BSX reps. While there could potentially be other interested acquirers (any ICD/pacemaker manufacturer), we do not expect additional bidders, since BSX and Elutia already have a close partnership. The transaction is expected to close in Q4. Our estimates remain unchanged.
Raymond James
$124
Buy
25.28%
Upside
Reiterated
09/08/25
Oppenheimer
$118→$125
Buy
26.29%
Upside
Upgraded
09/08/25
Bernstein
$130
Buy
31.34%
Upside
Reiterated
09/08/25
Jefferies
$130
Buy
31.34%
Upside
Reiterated
08/11/25
Bank of America Securities
$120
Buy
21.24%
Upside
Reiterated
08/06/25
TD Cowen
$115
Buy
16.19%
Upside
Reiterated
08/06/25
Truist Financial
$120→$125
Buy
26.29%
Upside
Reiterated
07/24/25
Robert W. Baird
$117→$123
Buy
24.27%
Upside
Reiterated
07/24/25
Mizuho Securities
$130→$140
Buy
41.44%
Upside
Reiterated
07/24/25
Canaccord Genuity
$117→$131
Buy
32.35%
Upside
Reiterated
07/24/25
Best Analysts Covering Boston Scientific
1 Month
xxx
Success Rate
20/27 ratings generated profit
Average Return
+2.08%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 74.07% of your transactions generating a profit, with an average return of +2.08% per trade.
3 Months
xxx
Success Rate
19/22 ratings generated profit
Average Return
+7.50%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 86.36% of your transactions generating a profit, with an average return of +7.50% per trade.
1 Year
Success Rate
24/24 ratings generated profit
Average Return
+32.78%
reiterated a buy rating 2 months ago
Copying Richard Newitter's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +32.78% per trade.
2 Years
xxx
Success Rate
29/29 ratings generated profit
Average Return
+63.56%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +63.56% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
BSX Analyst Recommendation Trends
Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
0
0
0
0
0
Buy
46
48
57
47
45
Hold
2
1
1
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
48
49
58
48
46
Each month's total comprises the sum of three months' worth of ratings.
BSX Financial Forecast
BSX Stock Forecast FAQ
What is BSX’s average 12-month price target, according to analysts?
Based on analyst ratings, Boston Scientific’s 12-month average price target is 126.00.
What is BSX’s upside potential, based on the analysts’ average price target?
Boston Scientific has 27.30% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is BSX a Buy, Sell or Hold?
Boston Scientific has a consensus rating of Strong Buy which is based on 21 buy ratings, 0 hold ratings and 0 sell ratings.
What is Boston Scientific’s price target?
The average price target for Boston Scientific is 126.00. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $140.00 ,the lowest forecast is $115.00. The average price target represents 27.30% Increase from the current price of $98.98.
The highest analyst price target is $140.00 ,the lowest forecast is $115.00. The average price target represents 27.30% Increase from the current price of $98.98.
What do analysts say about Boston Scientific?
Boston Scientific’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.
How can I buy shares of BSX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.